Sonoda, Y.; Sasaki, Y.; Gunji, A.; Shirai, H.; Araki, T.; Imamichi, S.; Onodera, T.; Rydén, A.-M.; Watanabe, M.; Itami, J.;
et al. Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under Parg Deficiency. Cancers 2020, 12, 1056.
https://doi.org/10.3390/cancers12041056
AMA Style
Sonoda Y, Sasaki Y, Gunji A, Shirai H, Araki T, Imamichi S, Onodera T, Rydén A-M, Watanabe M, Itami J,
et al. Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under Parg Deficiency. Cancers. 2020; 12(4):1056.
https://doi.org/10.3390/cancers12041056
Chicago/Turabian Style
Sonoda, Yuki, Yuka Sasaki, Akemi Gunji, Hidenori Shirai, Tomonori Araki, Shoji Imamichi, Takae Onodera, Anna-Margareta Rydén, Masatoshi Watanabe, Jun Itami,
and et al. 2020. "Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under Parg Deficiency" Cancers 12, no. 4: 1056.
https://doi.org/10.3390/cancers12041056
APA Style
Sonoda, Y., Sasaki, Y., Gunji, A., Shirai, H., Araki, T., Imamichi, S., Onodera, T., Rydén, A.-M., Watanabe, M., Itami, J., Honda, T., Ashizawa, K., Nakao, K., & Masutani, M.
(2020). Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under Parg Deficiency. Cancers, 12(4), 1056.
https://doi.org/10.3390/cancers12041056